Pyoderma gangrenosum successfully treated with perilesional granulocyte-macrophage colony stimulating factor. 1998

D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau

UI MeSH Term Description Entries
D007271 Injections, Intradermal The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer. Intradermal Injections,Injection, Intradermal,Intradermal Injection
D007871 Leg Ulcer Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes. Leg Ulcers,Ulcer, Leg,Ulcers, Leg
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016178 Granulocyte-Macrophage Colony-Stimulating Factor An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. CSF-GM,Colony-Stimulating Factor, Granulocyte-Macrophage,GM-CSF,Histamine-Producing Cell-Stimulating Factor,CSF-2,TC-GM-CSF,Tumor-Cell Human GM Colony-Stimulating Factor,Cell-Stimulating Factor, Histamine-Producing,Colony Stimulating Factor, Granulocyte Macrophage,Granulocyte Macrophage Colony Stimulating Factor,Histamine Producing Cell Stimulating Factor,Tumor Cell Human GM Colony Stimulating Factor
D017511 Pyoderma Gangrenosum An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.

Related Publications

D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
April 1997, The British journal of dermatology,
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
July 1991, Cancer,
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
January 2006, Skinmed,
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
January 2006, British journal of haematology,
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
July 1992, The New England journal of medicine,
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
July 1992, The New England journal of medicine,
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
January 1995, Dermatology (Basel, Switzerland),
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
October 2017, Japanese journal of clinical oncology,
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
January 1994, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
D Shpiro, and D Gilat, and L Fisher-Feld, and A Shemer, and I Gold, and H Trau
May 1993, The British journal of psychiatry : the journal of mental science,
Copied contents to your clipboard!